Whitman Walker Clinic — research payments reported

By program year

6 rows

Year	Kind	Amount	Payments
2024	Research	$94,421	20
2023	Research	$1,075	1
2022	Research	$6,530	2
2021	Research	$56,643	7
2020	Research	$101,143	53
2019	Research	$132,003	77

Breakdown

Who paid Research payments · program years 2019–2024

Merck Sharp & Dohme Corporation $296,320 139 payments
ViiV Healthcare Company $95,496 21 payments

Studies the money was for Research payments · program years 2019–2024

A Phase 4, Randomized, Open-Label, Three-Arm Study to Evaluate Impleme $72,411 12 payments
A Phase 3, Randomized, Active-Controlled, Double-blind Clinical Study to Evaluate a Switch to Doravirine,Islatravir DOR,ISL Once-Daily in Participants With HIV-1 Virologically Suppressed on Bictegravir,Emtricitabine,Tenofovir Alafenamide BIC,FTC,TAF $61,787 5 payments
A Phase IIa Multicenter, Open-Label Clinical Trial to Evaluate the Safety and Efficacy of MK-1439A in Treatment-Na ve HIV-1 Infected Subjects with Selected Non-Nucleoside Reverse Transcriptase Inhibitor NNRTI Transmitted Resistance Mutations $55,738 6 payments
A Phase 2B, Randomized, Double-Blind, Active-Comparator-Controlled, Dose-Ranging Clinical Trial to Evaluate the Safety, Tolerability, Antiretroviral-Activity, and Pharmacokinetics of MK 8591 Given in Combination with Doravirine DOR and Lamivudine 3TC in HIV-1-Infected Treatment-Na ve Adults $47,088 23 payments
A Phase 2B, Randomized, Double-Blind, Active-Comparator-Controlled, Dose-Ranging Clinical Trial to Evaluate the Safety, Tolerability, Antiretroviral-Activity, and Pharmacokinetics of MK 8591 Given in Combination with Doravirine DOR and Lamivudine 3TC in HIV-1-Infected Treatment-Na ve Adults $43,284 22 payments
A Phase III Multicenter, Open-Label, Randomized, Study to Evaluate a Switch to MK-1439A in HIV-1-Infected Subjects Virologically Suppressed on a Regimen of a Ritonavir-boosted Protease Inhibitor and Two Nucleoside Reverse Transcriptase Inhibitors NRTIs $24,861 13 payments
A Phase 4, Randomized, Open-Label, Two-Arm Study Evaluating Implementa $23,085 9 payments
A Phase 3, Randomized, Active-Controlled, Double-blind Clinical Study to Evaluate a Switch to Doravirine,Islatravir DOR,ISL Once-Daily in Participants With HIV-1 Virologically Suppressed on Bictegravir,Emtricitabine,Tenofovir Alafenamide BIC,FTC,TAF $15,075 2 payments
A Phase IIa Multicenter, Open-Label Clinical Trial to Evaluate the Safety and Efficacy of MK-1439A in Treatment-Na ve HIV-1 Infected Subjects with Selected Non-Nucleoside Reverse Transcriptase Inhibitor NNRTI Transmitted Resistance Mutations $15,064 15 payments
A Phase 2B, Randomized, Double-Blind, Active-Comparator-Controlled, Dose-Ranging Clinical Trial to Evaluate the Safety, Tolerability, Antiretroviral-Activity, and Pharmacokinetics of MK 8591 Given in Combination with Doravirine DOR and Lamivudine 3TC in HIV-1-Infected Treatment-Na Adults $13,741 2 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.